Tagged with HIV,

Africa While HIV has shifted from a death sentence to a manageable disease in most developed nations, there are several reasons why it still represents a huge global issue. It remains highly infectious and difficult to detect in the early stages of infection, while existing treatments are unavailable or too expensive…

Global The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this year’s edition that the 20 companies surveyed have firmly responded to access issues exposed by COVID-19. GSK remains at the…

Global In only 21 years, the Global Fund has made remarkable progress in the fight to eliminate HIV, tuberculosis (TB), and malaria across the world, contributing to 44 million lives saved. Cross-sectoral partnerships that leverage the skills and capabilities of governments, multilateral agencies, bilateral partners, civil society groups, people affected by…

Belgium Belgian doctor, researcher and professor, Stéphane De Wit has been with the St Pierre University Hospital in Brussels since 1983. Initially planning to specialize in intensive care, his first internship took him by chance to the infectious diseases department where he encountered his first patients with AIDS, met his mentor,…

Coronavirus Against the backdrop of an unprecedented collaborative global push to develop a COVID-19 vaccine, pharma industry executives and patient advocacy representatives at the BIO 2020 digital conference discussed the progress made towards developing a HIV vaccine and what developers of potential COVID-19 treatments and vaccines can learn from it.  …

Belgium Professor Stéphane De Wit, head of the Department of Infectious Diseases at St Pierre University Hospital outlines Belgium’s approach to tackling HIV treatment, how academia-industry collaboration is progressing in the country, and the potential of innovative new treatment nodes such as CAR-T.   In the past, we used to collaborate…

Romania Dana Constantinescu of GSK Romania reveals the importance of the affiliate to the regional group and how vaccines and HIV are driving its growth. She outlines how the affiliate’s portfolio reflects the global HIV portfolio and how it recently launched the 18th of the 22 vaccines GSK has. Constantinescu also…

Gilead Pavel Brezina, who led the establishment of Gilead’s affiliate in the Czech Republic and Slovakia seven years ago, shares the amazing journey of bringing the company’s life-saving treatments for HIV infection and chronic hepatitis C (CHC) to patients and presents the way the affiliate collaborates with authorities and associations to…

China Dr CJ Wang, CEO of Frontier Biotech, shares his exciting ten-year journey with Frontier and their distinctive focus on HIV drug development, with their flagship compound, Aikening®, launched in China in 2018; their ongoing efforts to develop more novel therapeutics; their ambitious internationalization strategy to bring their therapies to patients…

HIV Hopes have been raised of a cure for AIDS after a patient in London became free of the HIV virus following a bone marrow transplant.   Although it is not a viable large-scale strategy for a cure … these new findings reaffirm our belief that there exists a proof of…

China Rogers Luo Yongqing, global VP and general manager (China), Gilead Sciences, shares the key accomplishments of Gilead in China with six innovative products approved in just 15 months; the strategic significance of Gilead China as the newest affiliate for Gilead globally; and their commitment to maximizing patient access in China…

Colombia Newar Giraldo, General Manager of Humax in Colombia, discusses the company’s role in countering monopolistic situations, their recent focus on OTC medicines, as well as their selective internationalization strategy based on regulatory fit, and his intention to enter the nanotechnology and biosimilar sectors.  Could you introduce our readers to the…